Back to top
more

Revance Therapeutics, Inc. (RVNC)

(Delayed Data from NSDQ)

$25.80 USD

25.80
776,422

-0.26 (-0.30%)

Updated Mar 3, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (199 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed

Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.

Is a Surprise Coming for Revance (RVNC) This Earnings Season?

Revance (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Revance Therapeutics (RVNC) Surges: Stock Moves 5.5% Higher

Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

AbbVie's (ABBV) sBLA for Botox Gets Acceptance From FDA

AbbVie's (ABBV) sBLA for expanding the label of Botox for use in pediatric patients with neurogenic detrusor overactivity gets acceptance from the FDA.

Revance's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Revance Therapeutics.

How Revance (RVNC) Stock Stands Out in a Strong Industry

Revance (RVNC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Implied Volatility Surging for Revance Therapeutics (RVNC) Stock Options

Investors need to pay close attention to Revance Therapeutics (RVNC) stock based on the movements in the options market lately.

Will Revance Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Revance Therapeutics.

Kinjel Shah headshot

Allergan (AGN) Shareholders Approve Acquisition by AbbVie

Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

Will Revance Therapeutics (RVNC) Report Negative Q2 Earnings? What You Should Know

Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbbVie (ABBV) Shares Down So Far This Year: Here's Why

AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.

Revance Therapeutics (RVNC) Jumps: Stock Rises 5.2%

Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Will Revance Therapeutics (RVNC) Report Negative Earnings Next Week? What You Should Know

Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines

Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.

Revance Therapeutics (RVNC) Q3 Earnings Preview: What to Look Out For

Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy?

3 Drug/Biotech Stocks Up More Than 10% This Week

The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.

3 Drug/Biotech Stocks Up More Than 10% This Week

The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.

Revance's Neuromodulator Injection Positive in Phase III

Revance (RVNC) releases positive top-line data from two pivotal phase III trials, evaluating RT002 for reducing wrinkles between the brows. The studies meet both primary and secondary endpoints.